A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa-Reference-Cited by-同舟云学术

A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa

Published:2017-04-12 Issue:385 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Huttner Angela¹²³^ORCID,Combescure Christophe⁴,Grillet Stéphane⁵,Haks Mariëlle C.⁶^ORCID,Quinten Edwin⁶,Modoux Christine⁷,Agnandji Selidji Todagbe⁸⁹,Brosnahan Jessica⁸,Dayer Julie-Anne²,Harandi Ali M.¹⁰,Kaiser Laurent²^ORCID,Medaglini Donata¹¹¹²,Monath Tom¹³,Roux-Lombard Pascale⁷,Kremsner Peter G.⁸⁹,Ottenhoff Tom H. M.⁶,Siegrist Claire-Anne³⁵,

Affiliation:

1. Infection Control Program, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

2. Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

3. Center for Vaccinology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

4. Division of Clinical Epidemiology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

5. World Health Organization Collaborating Center for Vaccine Immunology, Faculty of Medicine, Geneva, Switzerland.

6. Department of Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands.

7. Division of Immunology and Allergy, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

8. Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.

9. Institut für Tropenmedizin, Universitätsklinikum Tübingen, and German Center for Infection Research, Tübingen, Germany.

10. Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

11. Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.

12. Sclavo Vaccines Association, Siena, Italy.

13. NewLink Genetics Corp., 94 Jackson Road, Devens, MA 01439, USA.

Abstract

A specific plasma signature reveals the critical role of monocytes in the VSV-vectored Ebola vaccine immunogenicity and safety.

Funder

European Commission Directorate-General for Research and Innovation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference64 articles.

1. Ebola Vaccine — An Urgent International Priority

2. Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses

3. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)

4. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine

5. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Refined innate plasma signature after rVSVΔG-ZEBOV-GP immunization is shared among adult cohorts in Europe and North America;Frontiers in Immunology;2024-01-03

2. Baseline gene signatures of reactogenicity to Ebola vaccination: a machine learning approach across multiple cohorts;Frontiers in Immunology;2023-11-08

3. Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus disease;Frontiers in Immunology;2023-09-04

4. Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV/MVA-BN-Filo;Cell Reports;2023-09

5. A review of criteria strictness in “Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials”;Vaccine;2023-08